Literature DB >> 26309693

Effect of edaravone on serum SP-A and arterial blood gas in patients with lobectomy.

Li Song1, Feng Xiong2, Xue-Juan Zhang3, Wei-Yi Liu1, Yang Zhao1, Wei Feng1.   

Abstract

OBJECTIVE: To discuss the effect of edaravone on serum pulmonary surfactant protein A (SP-A) and arterial blood gas (ABG) in patients with thoracoscopic lobectomy.
METHODS: 40 lung cancer patients with right side of lobectomy were randomly divided into control group (group C, 20 cases) and edaravone group (group E, 20 cases). Group E was treated edaravone (1 mg/kg) between induction and skin incision, dropping within 30 min; group C was treated with equivalent normal saline. The venous and arterial blood were collected in both groups immediately before incision (T0), after 1 h of one-lung ventilation 1 h (T1) and in 1 h after lungs ventilation (T2) for ABG analysis and measurement of serum SP-A level. Results After OLV, serum SP-A levels were significantly increased in both groups (P < 0.05); compared with group C, serum levels of SP-A were reduced (P < 0.05) and ABG was significantly improved in group E.
CONCLUSION: Edaravone can reduce serum SP-A levels in patients with lobectomy and alleviate acute lung injury to a certain extent in surgery.

Entities:  

Keywords:  ABG analysis; SP-A; edaravone; lung ventilation

Year:  2015        PMID: 26309693      PMCID: PMC4538190     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  10 in total

Review 1.  The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung.

Authors:  Francis X McCormack; Jeffrey A Whitsett
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

2.  Neuroprotective effects of edaravone: recent insights.

Authors:  Shailendra Kapoor
Journal:  J Neurol Sci       Date:  2013-05-24       Impact factor: 3.181

Review 3.  [VATS lobectomy for early-stage primary lung cancer].

Authors:  T Krueger; J Y Perentes; S Peters; H-B Ris; M Gonzalez
Journal:  Rev Med Suisse       Date:  2012-06-20

Review 4.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

Authors:  Jørgen Vestbo; Suzanne S Hurd; Alvar G Agustí; Paul W Jones; Claus Vogelmeier; Antonio Anzueto; Peter J Barnes; Leonardo M Fabbri; Fernando J Martinez; Masaharu Nishimura; Robert A Stockley; Don D Sin; Roberto Rodriguez-Roisin
Journal:  Am J Respir Crit Care Med       Date:  2012-08-09       Impact factor: 21.405

Review 5.  Research status and funding trends of lung cancer biomarkers.

Authors:  Cui Li; Wei Hong
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

6.  The effect of one-lung ventilation upon pulmonary inflammatory responses during lung resection.

Authors:  Yusuke Sugasawa; Keisuke Yamaguchi; Seiichiro Kumakura; Taisuke Murakami; Toyoki Kugimiya; Kenji Suzuki; Isao Nagaoka; Eiichi Inada
Journal:  J Anesth       Date:  2011-02-08       Impact factor: 2.078

7.  [Surfactant proteins-A and D as important serum markers for interstitial lung disease in patients with polymyositis or dermatomyositis].

Authors:  Fang Chen; Xiao-ming Shu; Dong-xue Wang; Yao Xie; Guo-chun Wang
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2012-08-21

8.  Beyond free radical scavenging: Beneficial effects of edaravone (Radicut) in various diseases (Review).

Authors:  Kiyoshi Kikuchi; Nobuyuki Takeshige; Naoki Miura; Yoko Morimoto; Takashi Ito; Salunya Tancharoen; Kei Miyata; Chiemi Kikuchi; Narumi Iida; Hisaaki Uchikado; Naohisa Miyagi; Naoto Shiomi; Terukazu Kuramoto; Ikuro Maruyama; Motohiro Morioka; Ko-Ichi Kawahara
Journal:  Exp Ther Med       Date:  2011-09-20       Impact factor: 2.447

9.  Accumulation of inhibitory kappaB-alpha as a mechanism contributing to the anti-inflammatory effects of surfactant protein-A.

Authors:  Yingda Wu; Stefanie Adam; Lutz Hamann; Holger Heine; Artur J Ulmer; Ute Buwitt-Beckmann; Cordula Stamme
Journal:  Am J Respir Cell Mol Biol       Date:  2004-08-12       Impact factor: 6.914

Review 10.  Pulmonary surfactant proteins A and D: innate immune functions and biomarkers for lung diseases.

Authors:  Hiroki Takahashi; Hitomi Sano; Hirofumi Chiba; Yoshio Kuroki
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.